EUVIMEDEUVIMED entdecken
Multizentrische Studie

Predictive factors for primary nonresponse to biologics in ulcerative colitis: a prospective multicenter study

Atsushi Yoshida iD, Tomohisa Takagi, Kousaku Kawashima, Kei Moriya, Shigeki Bamba, Shintaro Sagami, Tomoyuki Hayashi, Motoki Kaneko, Takeo Naito, Shuji Kanmura, Kohei Asaeda, Shunji Ishihara und 6 weitere

Journal of Gastroenterology · 2026

DOI: 10.1007/s00535-025-02313-0 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Gastroenterology, 2026. Verfasst von Atsushi Yoshida und 17 weiteren Autor:innen. Beteiligte Einrichtung: Center for Gastroenterology and Inflammatory Bowel Disease, Ofuna Chuo Hospital, Kamakura, Japan. atsushi-yoshida@ofunachuohp.net. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Biological Products, Antibodies, Antineutrophil Cytoplasmic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: We sought to evaluate the predictive value of protease-3 (PR3)-anti-neutrophil cytoplasmic antibodies (ANCAs) and myeloperoxidase (MPO)-ANCA for primary nonresponse (PNR) to biologic agents in patients with ulcerative colitis (UC). METHODS: A multicenter, prospective cohort study was conducted. Patients with UC who initiated biologic agents (anti-TNF, anti-integrin, or anti-IL12/23 agents) as their first-line therapy were enrolled. PNR was defined as failure to achieve a partial Mayo Score improvement of at least 2 points by weeks 14-16 or necessitating treatment modification. Logistic regression identified PNR predictors. RESULTS: Among 95 biologic-naïve UC patients, 38 received anti-TNF, 39 received anti-integrin, and 18 received anti-IL12/23 agents. PR3-ANCA positivity was observed in 47.4% of anti-TNF recipients. The PNR rate among PR3-ANCA-positive patients receiving anti-TNF therapy was 66.7%, significantly higher than in PR3-ANCA-negative patients (25.0%, P = 0.02). Multivariate logistic regression confirmed PR3-ANCA as an independent risk factor for PNR to anti-TNF therapy (OR 5.61; 95% CI 1.37-26.82; P = 0.02). By contrast, PR3-ANCA did not predict PNR to anti-integrin therapy, but the platelet-to-lymphocyte ratio (PLR) and the systemic immune-inflammatory index (SII) were identified as significant predictors. Only one of 95 patients tested positive for MPO-ANCA, precluding statistical analysis for its association with PNR. CONCLUSION: In patients with UC, PR3-ANCA is a significant predictor of PNR to anti-TNF therapy, but not to anti-integrin therapy. PLR and SII may predict PNR to anti-integrin therapy. PR3-ANCA could aid biologic selection, optimizing personalized UC treatment and healthcare resource utilization.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeBiological ProductsAntibodies, Antineutrophil CytoplasmicHumansMaleFemaleProspective StudiesAdultMiddle AgedPeroxidaseTumor Necrosis Factor-alphaPredictive Value of TestsIntegrinsLogistic ModelsRisk Factors

Stichwörter der Autor:innen

ANCAInflammatory bowel diseaseLymphocytePlateletPrognostic factor

Substanzen

Biological ProductsAntibodies, Antineutrophil CytoplasmicPeroxidaseTumor Necrosis Factor-alphaIntegrins

Autor:innen und Institutionen

  • Center for Gastroenterology and Inflammatory Bowel Disease, Ofuna Chuo Hospital, Kamakura, Japan. atsushi-yoshida@ofunachuohp.net.
  • Molecular Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
  • Inflammatory Bowel Disease Center, Shimane University Hospital, Izumo, Japan.
  • Nara Prefecture General Medical Center, Nara, Japan.
  • Department of Fundamental Nursing, Shiga University of Medical Science, Otsu, Japan.
  • Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Minato, Japan.

ORCID-Profile: Atsushi Yoshida

Zitieren

APA

Yoshida, A., Takagi, T., Kawashima, K., Moriya, K., Bamba, S., Sagami, S., Hayashi, T., Kaneko, M., Naito, T., Kanmura, S., Asaeda, K., Ishihara, S., Nagamatsu, S., Endo, Y., Ueno, F., Morizane, T., Matsuoka, K., & Hibi, T. (2026). Predictive factors for primary nonresponse to biologics in ulcerative colitis: a prospective multicenter study. Journal of Gastroenterology. https://doi.org/10.1007/s00535-025-02313-0

Vancouver

Yoshida A, Takagi T, Kawashima K, Moriya K, Bamba S, Sagami S, et al. Predictive factors for primary nonresponse to biologics in ulcerative colitis: a prospective multicenter study. Journal of Gastroenterology. 2026. doi:10.1007/s00535-025-02313-0

BibTeX
@article{Yoshida2026,
  author = {Yoshida, Atsushi and Takagi, Tomohisa and Kawashima, Kousaku and Moriya, Kei and Bamba, Shigeki and Sagami, Shintaro and Hayashi, Tomoyuki and Kaneko, Motoki and Naito, Takeo and Kanmura, Shuji and Asaeda, Kohei and Ishihara, Shunji and Nagamatsu, Shinsaku and Endo, Yutaka and Ueno, Fumiaki and Morizane, Toshio and Matsuoka, Katsuyoshi and Hibi, Toshifumi},
  title = {Predictive factors for primary nonresponse to biologics in ulcerative colitis: a prospective multicenter study},
  journal = {Journal of Gastroenterology},
  year = {2026},
  doi = {10.1007/s00535-025-02313-0}
}
Kostenlos starten →